Escitalopram in Patients With Social Anxiety Disorder

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment period, and to evaluate safety of escitalopram.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lundbeck A/S
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• The patient suffers from SAD, diagnosed according to ICD-10 (International Classification of Diseases)

• The patient meets criteria set in the national SPC for escitalopram

• The patient is, in the opinion of the investigator, otherwise healthy on the basis of a physical examination, medical history and vital signs

Exclusion Criteria:

• The patient has/has had an alcohol or drug abuse-related disorder, as defined in ICD-10

• The patient has contraindications to escitalopram

• The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to escitalopram

• The patient has a serious illness and/or serious sequelae thereof, including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance

• The patient is pregnant or breast-feeding

• The patient, if a woman of childbearing potential, is not using adequate contraception